X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.biospectrumasia.com/news/25/18382/daiichi-sankyo-discontinues-development-of-nafamostat-in-japan-for-covid-19-treatment.html
https://www.clinicaltrialsarena.com/news/sun-pharma-nafamostat-trial/
https://www.livemint.com/companies/news/covid-19-sun-pharma-gets-dcgi-nod-for-nafamostat-clinical-trial-in-patients-11590749722996.html
http://www.pharmafile.com/news/548753/korean-researchers-find-drug-more-effective-treating-covid-19-remdesivir
https://www.biospace.com/article/releases/ensysce-a-california-based-biotech-company-with-a-mission-to-solve-the-opioid-crisis-exploring-a-treatment-for-covid-19-/
Market Place
Share 
